Immunization of transgenic animals producing human antibodies has been the most successful approach to obtaining fully human therapeutic antibodies. They allow for the rapid generation of candidate antibodies to multiple targets of interest and the ability to transition lead candidates to clinical development without undergoing time consuming and costly steps such as humanization or affinity maturation of antibodies from structural display libraries.

Summary

Antibody Solutions has successfully generated therapeutic candidate antibodies from multiple transgenic animal platforms. With a fully optimized discovery platform, OmniRatTM, OmniMouseTM , Harbour H2L2TM, Trianni MouseTM, and Alloy Therapeutics ATX-GxTM mouse all offer robust “nearnormal” immune response and effective generation of antibodies featuring fully human variable regions.

Download this poster

We invite you to download our poster that details this research study, including our antibody discovery strategy as well as the Spike protein reagents, screening assay formats, and more that we utilized.

Authors

Joshua Lowitz, Glen Lin, Jennifer Somera, Leonel Santibanez-Vargas, Catherine Vo, Edgar Rodriguez, Billy Nguyen, Michael Trang, John Nichols and John S. Kenney Antibody Solutions, Sunnyvale, CA, USA